Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity

Désirée Bonci, Maria Musumeci, Valeria Coppola, Antonio Addario, Concetta Conticello, Michael Hahne, Massimo Gulisano, Francesco Grignani, Ruggero De Maria

Research output: Contribution to journalArticlepeer-review


Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia. APRIL (A Proliferation Inducing Ligand) is a member of the tumor necrosis factor superfamily that plays a key role in normal B-cell development, while promoting survival and proliferation of malignant B cells. We investigated APRIL expression and activity in acute myeloid leukemia. We found that APRIL mRNA and protein, including the secreted form, are expressed in leukemic cells of patients with M0, M2 and M4 acute myeloid leukemia subtypes but not in normal hematopoietic progenitors. Retrovirus-mediated APRIL expression in normal hematopoietic progenitors confers resistance to chemotherapeutic drugs-induced apoptosis. Conversely, blocking APRIL function by recombinant soluble APRIL receptors increased chemotherapeutic drugs-induced cell adeath in acute myeloid leukemia cells. These results indicate that APRIL acts in an autocrine fashion to protect acute myeloid leukemia cells from drug-induced death and foresee a therapeutic potential of APRIL antagonists in the treatment of acute myeloid leukemia.

Original languageEnglish
Pages (from-to)1899-1902
Number of pages4
Issue number12
Publication statusPublished - Dec 2008


  • Acute myeloid leukemia
  • Chemosensitivity

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity'. Together they form a unique fingerprint.

Cite this